Premium
Mutant p53 expression in prostate carcinoma
Author(s) -
van Veldhuizen Peter J.,
Sadasivan Raj,
Garcia Fernando,
Austenfeld Mark S.,
Stephens Ronald L.
Publication year - 1993
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.2990220104
Subject(s) - immunostaining , immunohistochemistry , monoclonal antibody , stromal cell , prostate , pathology , biology , prostate cancer , tumor suppressor gene , cytoplasm , heat shock protein , hyperplasia , mutant , cancer research , carcinoma , stroma , antibody , cancer , medicine , carcinogenesis , gene , microbiology and biotechnology , immunology , biochemistry , genetics
The expression of the mutant p53 tumor suppressor gene was evaluated in 33 human prostate carcinomas. Using an immunohistochemical method with monoclonal antibodies PAb 1801 and PAb 240, 26 (79%) tumors demonstrated positive immunostaining for mutant p53. Only areas of glandular tumor were positive, with adjacent stromal elements and areas of glandular hyperplasia being negative. The predominant staining pattern was cytoplasmic. This pattern may be related to p53 binding to certain heat shock proteins (HSP 72/73), as a monoclonal antibody to these proteins demonstrated a cytoplasmic location as well. These results demonstrate that abnormal p53 expression is a frequent event in prostate cancer. © 1993 Wiley‐Liss, Inc.